Cidara Therapeutics (CDTX) Competitors $25.93 -0.24 (-0.92%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$25.93 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. AMPH, CALT, GPCR, AUPH, WVE, NAGE, MLYS, RCUS, SYRE, and AKBAShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics Cidara Therapeutics (NASDAQ:CDTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations. Do analysts recommend CDTX or AMPH? Cidara Therapeutics currently has a consensus target price of $42.00, indicating a potential upside of 61.97%. Amphastar Pharmaceuticals has a consensus target price of $32.33, indicating a potential upside of 24.12%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable valuation and earnings, CDTX or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$302K1,077.30-$22.93M-$29.47-0.88Amphastar Pharmaceuticals$730.66M1.68$137.54M$2.769.44 Does the media prefer CDTX or AMPH? In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Cidara Therapeutics. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 5 mentions for Cidara Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.93 beat Cidara Therapeutics' score of 0.43 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in CDTX or AMPH? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer CDTX or AMPH? Cidara Therapeutics received 73 more outperform votes than Amphastar Pharmaceuticals when rated by MarketBeat users. Likewise, 70.61% of users gave Cidara Therapeutics an outperform vote while only 65.83% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCidara TherapeuticsOutperform Votes46670.61% Underperform Votes19429.39% Amphastar PharmaceuticalsOutperform Votes39365.83% Underperform Votes20434.17% Which has more volatility and risk, CDTX or AMPH? Cidara Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Is CDTX or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Cidara Therapeutics' net margin of -289.05%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara Therapeutics-289.05% -69.64% -33.73% Amphastar Pharmaceuticals 21.80%26.44%11.89% SummaryAmphastar Pharmaceuticals beats Cidara Therapeutics on 11 of the 19 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$325.34M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-1.0233.3227.1720.06Price / Sales1,077.30469.84410.88157.10Price / CashN/A168.6838.2534.64Price / Book-14.253.457.094.70Net Income-$22.93M-$72.35M$3.23B$247.88M7 Day Performance7.82%6.23%2.91%2.66%1 Month Performance33.45%16.53%9.09%6.40%1 Year Performance80.45%-16.90%31.75%14.07% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.2873 of 5 stars$25.93-0.9%$42.00+62.0%+91.4%$325.34M$302K-1.0290Analyst ForecastHigh Trading VolumeAMPHAmphastar Pharmaceuticals3.6564 of 5 stars$26.62+2.4%$32.33+21.5%-36.7%$1.25B$730.66M8.871,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.291 of 5 stars$20.51-2.9%$76.50+273.0%-54.6%$1.18BN/A-27.72136News CoveragePositive NewsAnalyst RevisionAUPHAurinia Pharmaceuticals3.3319 of 5 stars$8.14-0.6%$11.50+41.3%+45.8%$1.10B$247.30M-54.26300Positive NewsAnalyst RevisionWVEWave Life Sciences4.4506 of 5 stars$7.05-2.4%$21.17+200.2%+16.0%$1.09B$104.94M-6.35240Positive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4779 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120News CoverageAnalyst ForecastMLYSMineralys Therapeutics3.3374 of 5 stars$16.19+0.4%$38.00+134.7%+19.7%$1.06BN/A-4.4528Analyst ForecastRCUSArcus Biosciences2.5159 of 5 stars$9.86-1.1%$24.13+144.7%-41.9%$1.04B$141M-3.13500Options VolumeAnalyst RevisionGap UpSYRESpyre Therapeutics2.1734 of 5 stars$17.16+1.1%$53.40+211.2%-52.6%$1.03B$890K-2.3073AKBAAkebia Therapeutics4.4679 of 5 stars$3.83-3.5%$6.75+76.2%+221.6%$1.01B$184.91M-16.65430High Trading Volume Related Companies and Tools Related Companies Amphastar Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Aurinia Pharmaceuticals Competitors Wave Life Sciences Competitors Niagen Bioscience Competitors Mineralys Therapeutics Competitors Arcus Biosciences Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts